Home > Insider Trading > Filing (0000947871-24-000498)

Filing Details

Accession Number:: 0000947871-24-000498
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-20 16:39:38
Reporting Period:: 2024-05-15

Accepted Time:: 2024-05-20 16:39:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1739174	Biomx Inc.	PHGE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1282930	L Carl Gordon	C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686	No	No	Yes	No
1569590	Ltd. Gp Israel Orbimed	5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686	No	No	Yes	No
1569821	Partnership Limited Gp Biofund Israel Orbimed	5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686	No	No	Yes	No
1706399	Erez Chimovits	C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-15	9,280,408	$0.24	13,797,997	No	4	X	Indirect	See footnotes
Common Stock	Disposition	2024-05-15	24,344	$0.38	13,773,653	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (Right to Buy)	Disposition	2024-05-15	9,280,408	$0.00	9,280,408	$0.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2023-05-04	2033-05-04	No	4	X	Indirect

Footnotes

On May 15, 2024, OrbiMed Israel Partners Limited Partnership ("OIP") exercised pre-funded warrants ("Warrants") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory "profits" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions.
These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.